{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T01:37:17Z","timestamp":1787621837643,"version":"build-2736575974"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T00:00:00Z","timestamp":1736726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T00:00:00Z","timestamp":1736726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Imaging Biol"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s11307-025-01982-w","type":"journal-article","created":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T13:25:42Z","timestamp":1736774742000},"page":"131-141","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["18F-FAPI-42 PET\/CT and 18F-FDG PET\/CT in Patients with Malignant Digestive System Neoplasms: A Head-to-Head Comparative Study"],"prefix":"10.1007","volume":"27","author":[{"given":"Min","family":"Xiong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HongJi","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingmin","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yipei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoming","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Nan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,13]]},"reference":[{"key":"1982_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A (2023) Cancer statistics, 2023. CA Cancer J Clin 73:17\u201348. https:\/\/doi.org\/10.3322\/caac.21763","journal-title":"CA Cancer J Clin"},{"key":"1982_CR2","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1007\/s00259-020-04769-z","volume":"47","author":"H Chen","year":"2020","unstructured":"Chen H, Pang Y, Wu J, Zhao L, Hao B, Wu J et al (2020) Comparison of [68 Ga] Ga-DOTA-FAPI-04 and [18 F] FDG PET\/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer. Eur J Nucl Med Mol Imaging 47:1820\u20131832. https:\/\/doi.org\/10.1007\/s00259-020-04769-z","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1982_CR3","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/cncr.10309.abs","volume":"96","author":"RL Zimmerman","year":"2002","unstructured":"Zimmerman RL, Burke M, Young NA, Solomides CC, Bibbo M (2002) Diagnostic utility of Glut-1 and CA 15\u20133 in discriminating adenocarcinoma from hepatocellular carcinoma in liver tumors biopsied by fine-needle aspiration. Cancer Cytopathol: Interdiscip Int J Am Cancer Soc 96:53\u201357. https:\/\/doi.org\/10.1002\/cncr.10309.abs","journal-title":"Cancer Cytopathol: Interdiscip Int J Am Cancer Soc"},{"key":"1982_CR4","doi-asserted-by":"publisher","first-page":"110048","DOI":"10.1016\/j.ejrad.2021.110048","volume":"145","author":"A Seko-Nitta","year":"2021","unstructured":"Seko-Nitta A, Nagatani Y, Murakami Y, Watanabe Y, Nitta N, Murata K et al (2021) 18F-fluorodeoxyglucose uptake in advanced gastric cancer correlates with histopathological subtypes and volume of tumor stroma. Eur J Radiol 145:110048. https:\/\/doi.org\/10.1016\/j.ejrad.2021.110048","journal-title":"Eur J Radiol"},{"key":"1982_CR5","doi-asserted-by":"publisher","unstructured":"Hu K, Wang L, Wu H, Huang S, Tian Y, Wang Q et al (2022) [18 F] FAPI-42 PET imaging in cancer patients: optimal acquisition time, biodistribution, and comparison with [68 Ga] Ga-FAPI-04. Eur J Nucl Med Mol Imaging 49:2833\u20132843. https:\/\/doi.org\/10.1007\/s00259-021-05646-z","DOI":"10.1007\/s00259-021-05646-z"},{"key":"1982_CR6","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1016\/j.ejrad.2016.08.006","volume":"85","author":"V Lopez-Lopez","year":"2016","unstructured":"Lopez-Lopez V, Cascales-Campos P, Gil J, Frutos L, Andrade R, Fuster-Qui\u00f1onero M et al (2016) Use of 18F-FDG PET\/CT in the preoperative evaluation of patients diagnosed with peritoneal carcinomatosis of ovarian origin, candidates to cytoreduction and hipec. A pending issue. Eur J Radiol 85:1824\u20131828. https:\/\/doi.org\/10.1016\/j.ejrad.2016.08.006","journal-title":"Eur J Radiol"},{"key":"1982_CR7","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.2967\/jnumed.123.265594","volume":"64","author":"M Ora","year":"2023","unstructured":"Ora M, Soni N, Nazar AH, Dixit M, Singh R, Puri S et al (2023) Fibroblast activation protein inhibitor-based radionuclide therapies: current status and future directions. J Nucl Med 64:1001\u20131008. https:\/\/doi.org\/10.2967\/jnumed.123.265594","journal-title":"J Nucl Med"},{"key":"1982_CR8","doi-asserted-by":"publisher","first-page":"11192","DOI":"10.3390\/ijms222011192","volume":"22","author":"G Treglia","year":"2021","unstructured":"Treglia G, Muoio B, Roustaei H, Kiamanesh Z, Aryana K, Sadeghi R (2021) Head-to-head comparison of fibroblast activation protein inhibitors (FAPI) radiotracers versus [18F] F-FDG in oncology: a systematic review. Int J Mol Sci 22:11192. https:\/\/doi.org\/10.3390\/ijms222011192","journal-title":"Int J Mol Sci"},{"key":"1982_CR9","doi-asserted-by":"publisher","first-page":"490","DOI":"10.2214\/AJR.22.28402","volume":"220","author":"Z Gege","year":"2023","unstructured":"Gege Z, Xueju W, Bin J (2023) Head-to-head comparison of 68Ga-FAPI PET\/CT and FDG PET\/CT for the detection of peritoneal metastases: systematic review and meta-analysis. Am J Roentgenol 220:490\u2013498. https:\/\/doi.org\/10.2214\/AJR.22.28402","journal-title":"Am J Roentgenol"},{"key":"1982_CR10","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1007\/s00259-020-05070-9","volume":"48","author":"X Shi","year":"2021","unstructured":"Shi X, Xing H, Yang X, Li F, Yao S, Congwei J et al (2021) Comparison of PET imaging of activated fibroblasts and 18 F-FDG for diagnosis of primary hepatic tumours: a prospective pilot study. Eur J Nucl Med Mol Imaging 48:1593\u20131603. https:\/\/doi.org\/10.1007\/s00259-020-05070-9","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1982_CR11","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41573-018-0004-1","volume":"18","author":"X Chen","year":"2019","unstructured":"Chen X, Song E (2019) Turning foes to friends: targeting cancer-associated fibroblasts. Nat Rev Drug Discovery 18:99\u2013115. https:\/\/doi.org\/10.1038\/s41573-018-0004-1","journal-title":"Nat Rev Drug Discovery"},{"issue":"463\u201379","key":"1982_CR12","doi-asserted-by":"publisher","first-page":"e10","DOI":"10.1016\/j.ccell.2018.01.011","volume":"33","author":"A Costa","year":"2018","unstructured":"Costa A, Kieffer Y, Scholer-Dahirel A, Pelon F, Bourachot B, Cardon M et al (2018) Fibroblast heterogeneity and immunosuppressive environment in human breast cancer. Cancer Cell 33(463\u201379):e10. https:\/\/doi.org\/10.1016\/j.ccell.2018.01.011","journal-title":"Cancer Cell"},{"key":"1982_CR13","doi-asserted-by":"publisher","first-page":"693640","DOI":"10.3389\/fonc.2021.693640","volume":"11","author":"H Wang","year":"2021","unstructured":"Wang H, Zhu W, Ren S, Kong Y, Huang Q, Zhao J et al (2021) 68Ga-FAPI-04 versus 18F-FDG PET\/CT in the detection of hepatocellular carcinoma. Front Oncol 11:693640. https:\/\/doi.org\/10.3389\/fonc.2021.693640","journal-title":"Front Oncol"},{"key":"1982_CR14","doi-asserted-by":"publisher","first-page":"e420","DOI":"10.1097\/RLU.0000000000004751","volume":"48","author":"G Al\u00e7\u0131n","year":"2023","unstructured":"Al\u00e7\u0131n G, Arslan E, Aksoy T, Cin M, Fenercio\u011flu \u00d6E, Beyhan E et al (2023) 68Ga-FAPI-04 PET\/CT in selected breast cancer patients with low FDG affinity: a head-to-head comparative study. Clin Nucl Med 48:e420\u2013e430. https:\/\/doi.org\/10.1097\/RLU.0000000000004751","journal-title":"Clin Nucl Med"},{"key":"1982_CR15","doi-asserted-by":"publisher","first-page":"2779","DOI":"10.1007\/s00330-022-09251-y","volume":"33","author":"C Li","year":"2023","unstructured":"Li C, Tian Y, Chen J, Jiang Y, Xue Z, Xing D et al (2023) Usefulness of [68Ga] FAPI-04 and [18F] FDG PET\/CT for the detection of primary tumour and metastatic lesions in gastrointestinal carcinoma: a comparative study. Eur Radiol 33:2779\u20132791. https:\/\/doi.org\/10.1007\/s00330-022-09251-y","journal-title":"Eur Radiol"},{"key":"1982_CR16","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1007\/s00259-022-06022-1","volume":"50","author":"J Zhang","year":"2023","unstructured":"Zhang J, He Q, Jiang S, Li M, Xue H, Zhang D et al (2023) [18F] FAPI PET\/CT in the evaluation of focal liver lesions with [18F] FDG non-avidity. Eur J Nucl Med Mol Imaging 50:937\u2013950. https:\/\/doi.org\/10.1007\/s00259-022-06022-1","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1982_CR17","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1007\/s00259-012-2096-x","volume":"39","author":"V Goh","year":"2012","unstructured":"Goh V, Sarker D, Osmany S, Cook G (2012) Functional imaging techniques in hepatocellular carcinoma. Eur J Nucl Med Mol Imaging 39:1070\u20131079. https:\/\/doi.org\/10.1007\/s00259-012-2096-x","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1982_CR18","first-page":"1811","volume":"36","author":"T Torizuka","year":"1995","unstructured":"Torizuka T, Tamaki N, Inokuma T, Magata Y, Sasayama S, Yonekura Y et al (1995) In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med 36:1811\u20131817","journal-title":"J Nucl Med"},{"key":"1982_CR19","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s12149-007-0076-1","volume":"22","author":"B Paudyal","year":"2008","unstructured":"Paudyal B, Oriuchi N, Paudyal P, Tsushima Y, Higuchi T, Miyakubo M et al (2008) Clinicopathological presentation of varying 18 F-FDG uptake and expression of glucose transporter 1 and hexokinase II in cases of hepatocellular carcinoma and cholangiocellular carcinoma. Ann Nucl Med 22:83\u201386. https:\/\/doi.org\/10.1007\/s12149-007-0076-1","journal-title":"Ann Nucl Med"},{"key":"1982_CR20","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s40001-023-00997-9","volume":"28","author":"Y Wang","year":"2023","unstructured":"Wang Y, Luo W, Li Y (2023) [68Ga] Ga-FAPI-04 PET MRI\/CT in the evaluation of gastric carcinomas compared with [18F]-FDG PET MRI\/CT: a meta-analysis. Eur J Med Res 28:34. https:\/\/doi.org\/10.1186\/s40001-023-00997-9","journal-title":"Eur J Med Res"},{"key":"1982_CR21","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.3390\/cancers11081052","volume":"11","author":"I Gonz\u00e1lez-Borja","year":"2019","unstructured":"Gonz\u00e1lez-Borja I, Vi\u00fadez A, Go\u00f1i S, Santamaria E, Carrasco-Garc\u00eda E, P\u00e9rez-Sanz J et al (2019) Omics approaches in pancreatic adenocarcinoma. Cancers 11:1052. https:\/\/doi.org\/10.3390\/cancers11081052","journal-title":"Cancers"},{"key":"1982_CR22","doi-asserted-by":"publisher","first-page":"779","DOI":"10.2967\/jnumed.120.253062","volume":"62","author":"M R\u00f6hrich","year":"2021","unstructured":"R\u00f6hrich M, Naumann P, Giesel FL, Choyke PL, Staudinger F, Wefers A et al (2021) Impact of 68Ga-FAPI PET\/CT imaging on the therapeutic management of primary and recurrent pancreatic ductal adenocarcinomas. J Nucl Med 62:779\u2013786. https:\/\/doi.org\/10.2967\/jnumed.120.253062","journal-title":"J Nucl Med"},{"key":"1982_CR23","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1007\/s00259-022-05729-5","volume":"49","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Jia G, Pan G, Cao K, Yang Q, Meng H et al (2022) Comparison of the diagnostic efficacy of 68 Ga-FAPI-04 PET\/MR and 18F-FDG PET\/CT in patients with pancreatic cancer. Eur J Nucl Med Mol Imaging 49:2877\u20132888. https:\/\/doi.org\/10.1007\/s00259-022-05729-5","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1982_CR24","doi-asserted-by":"publisher","first-page":"737827","DOI":"10.3389\/fonc.2021.737827","volume":"11","author":"J Wu","year":"2021","unstructured":"Wu J, Wang Y, Liao T, Rao Z, Gong W, Ou L et al (2021) Comparison of the relative diagnostic performance of [68Ga] Ga-DOTA-FAPI-04 and [18F] FDG PET\/CT for the detection of bone metastasis in patients with different cancers. Front Oncol 11:737827. https:\/\/doi.org\/10.3389\/fonc.2021.737827","journal-title":"Front Oncol"},{"key":"1982_CR25","doi-asserted-by":"publisher","first-page":"4179","DOI":"10.1021\/acs.molpharmaceut.1c00566","volume":"18","author":"H Ma","year":"2021","unstructured":"Ma H, Li F, Shen G, Cai H, Liu W, Lan T et al (2021) Synthesis and preliminary evaluation of 131I-labeled FAPI tracers for cancer theranostics. Mol Pharm 18:4179\u20134187. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.1c00566","journal-title":"Mol Pharm"},{"key":"1982_CR26","doi-asserted-by":"publisher","first-page":"3651","DOI":"10.1007\/s00259-022-05842-5","volume":"49","author":"D Zboralski","year":"2022","unstructured":"Zboralski D, Hoehne A, Bredenbeck A, Schumann A, Nguyen M, Schneider E et al (2022) Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy. Eur J Nucl Med Mol Imaging 49:3651\u20133667. https:\/\/doi.org\/10.1007\/s00259-022-05842-5","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1982_CR27","doi-asserted-by":"publisher","first-page":"563","DOI":"10.2967\/jnumed.119.233122","volume":"61","author":"T Watabe","year":"2020","unstructured":"Watabe T, Liu Y, Kaneda-Nakashima K, Shirakami Y, Lindner T, Ooe K et al (2020) Theranostics targeting fibroblast activation protein in the tumor stroma: 64Cu-and 225Ac-labeled FAPI-04 in pancreatic cancer xenograft mouse models. J Nucl Med 61:563\u2013569. https:\/\/doi.org\/10.2967\/jnumed.119.233122","journal-title":"J Nucl Med"},{"key":"1982_CR28","doi-asserted-by":"publisher","unstructured":"Liu Y, Watabe T, Kaneda-Nakashima K, Shirakami Y, Naka S, Ooe K et al (2022) Fibroblast activation protein targeted therapy using [177 Lu] FAPI-46 compared with [225 Ac] FAPI-46 in a pancreatic cancer model. Eur J Nucl Med Mol Imaging 49:871\u2013880. https:\/\/doi.org\/10.1007\/s00259-021-05554-2","DOI":"10.1007\/s00259-021-05554-2"},{"key":"1982_CR29","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.265712","author":"M Wu","year":"2023","unstructured":"Wu M, Wang Y, Yang Q, Wang X, Yang X, Xing H et al (2023) Comparison of baseline 68Ga-FAPI and 18F-FDG PET\/CT for prediction of response and clinical outcome in patients with unresectable hepatocellular carcinoma treated with PD-1 inhibitor and lenvatinib. J Nucl Med. https:\/\/doi.org\/10.2967\/jnumed.123.265712","journal-title":"J Nucl Med"},{"key":"1982_CR30","doi-asserted-by":"publisher","first-page":"e334","DOI":"10.1097\/RLU.0000000000005255","volume":"49","author":"SS Banihashemian","year":"2024","unstructured":"Banihashemian SS, Bayat M, Pirayesh E, Divband G, Abolhosseini A, Akbari ME (2024) First experience of radionuclide therapy with 177Lu-FAPI-2286 in a patient with metastatic mediastinal sarcoma. Clin Nucl Med 49:e334\u2013e337. https:\/\/doi.org\/10.1097\/RLU.0000000000005255","journal-title":"Clin Nucl Med"},{"key":"1982_CR31","doi-asserted-by":"publisher","first-page":"e243","DOI":"10.1097\/RLU.0000000000004021","volume":"47","author":"F Kaghazchi","year":"2022","unstructured":"Kaghazchi F, Aghdam RA, Haghighi S, Vali R, Adinehpour Z (2022) 177Lu-FAPI therapy in a patient with end-stage metastatic pancreatic adenocarcinoma. Clin Nucl Med 47:e243\u2013e245. https:\/\/doi.org\/10.1097\/RLU.0000000000004021","journal-title":"Clin Nucl Med"}],"container-title":["Molecular Imaging and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-025-01982-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11307-025-01982-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-025-01982-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T10:52:56Z","timestamp":1738925576000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11307-025-01982-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,13]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["1982"],"URL":"https:\/\/doi.org\/10.1007\/s11307-025-01982-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4958582\/v1","asserted-by":"object"}]},"ISSN":["1536-1632","1860-2002"],"issn-type":[{"value":"1536-1632","type":"print"},{"value":"1860-2002","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,13]]},"assertion":[{"value":"22 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Ethics Committee of The Second Affiliated Hospital, Guangzhou Medical University (study Nr.: 2023-hg-ks-36).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"The authors declare that they have no conflict of interest with regard to this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}